

# Implementation of Synthesized Two-dimensional Mammography in a Population-based Digital Breast Tomosynthesis Screening Program

**Zuckerman SP,** Conant EF, Keller BM, Maidment AD, Barufaldi B, Weinstein SP, Synnestvedt M, McDonald ES.

Radiology, 2016 Jul 28: 160366 [Epub ahead of print].

# **Objective**

The goal of this study was to compare the performance of synthesized 2D mammography in a screening population utilizing only digital breast tomosynthesis (DBT) with a generated 2D images. A comparison of recall rates and cancer detection rates to prior outcomes of full field digital mammography (FFDM) and DBT.

## **Materials and Methods**

The study utilized prior screening studies, from October 2011 to February 2013 from 15,571 women. Recall rates, cancer detection and biopsy rates were compared to 5,366 exams acquired between January and June 2015. The radiation dose from these exams was also reviewed and compared. The examinations were performed with the Hologic Selenia® Dimensions® system and C-View™ software.

### Results

The study results conclude that DBT exams with generated 2D images are comparable to FFDM + DBT exams in their effectiveness at detecting invasive breast cancers (4.1/1000 and 3.9/1000, respectively). In evaluating the cancer detection rate between the two, there was no significant difference noted. Additionally, the low-dose screening option demonstrated an increase in the probability of a patient's biopsy finding cancer, in comparison to traditional FFDM + DBT exams (39% and 27%, respectively). Both screening methods had comparable performance, but the associated dose was significantly reduced by 39% with the adoption of a generated 2D image.

#### Conclusion

Screening with DBT and generated 2D images resulted in similar outcomes compared to FFDM + DBT imaging. The benefit is the decrease in radiation dose when compared to FFDM + DBT.

hologic.com | info@hologic.com | +1.781.999.7300

MED-00208 Rev. 001 (09/16) US © 2016 Hologic, Inc. All rights reserved. Hologic, C-View, Dimensions, Selenia and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to womenshealth@hologic.com.